Marshall Wace
KYMR icon

Marshall Wace’s Kymera Therapeutics KYMR Stock Holding History

Marshall Wace’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2M Buy
+167,517
New +$14.4M 0.02% 743
2026
Q1 		– Sell
-38,022
Closed -$2.96M – 3481
2025
Q4 		$2.96M Sell
38,022
-321,054
-89% -$21.7M ﹤0.01% 1395
2025
Q3 		$20.3M Buy
359,076
+89,792
+33% +$4.05M 0.02% 647
2025
Q2 		$11.8M Buy
269,284
+67,384
+33% +$2.32M 0.01% 788
2025
Q1 		$5.53M Buy
201,900
+195,065
+2,854% +$7.11M 0.01% 1013
2024
Q4 		$275K Sell
6,835
-110,846
-94% -$5.01M ﹤0.01% 2255
2024
Q3 		$5.57M Sell
117,681
-258,881
-69% -$11.4M 0.01% 957
2024
Q2 		$11.2M Sell
376,562
-196,364
-34% -$6.8M 0.02% 683
2024
Q1 		$23M Buy
+572,926
New +$20.5M 0.04% 463
2023
Q4 		– Sell
-54,837
Closed -$762K – 2413
2023
Q3 		$762K Sell
54,837
-209,081
-79% -$4.2M ﹤0.01% 1582
2023
Q2 		$6.07M Buy
+263,918
New +$7.56M 0.01% 939
2021
Q2 		– Sell
-14,698
Closed -$571K – 2865
2021
Q1 		$571K Buy
+14,698
New +$885K ﹤0.01% 1891

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marshall Wace's KYMR Position: Q2 2026 in Review

Marshall Wace opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 167,517 shares worth $19.2M. The stake represents 0.02% of the portfolio and ranks #743 among its holdings. This is a return to the name: Marshall Wace previously reported a position in KYMR as recently as Q4 2025.

Marshall Wace first reported a position in KYMR in Q1 2021 and has held it in 12 quarters since. The position peaked at $23M in Q1 2024. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Marshall Wace held 167,517 shares of Kymera Therapeutics worth $19.2M as of Q2 2026.
  • Kymera Therapeutics was a new Marshall Wace position in Q2 2026.
  • Kymera Therapeutics made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #743 holding.
  • Marshall Wace first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Marshall Wace's Kymera Therapeutics position peaked at $23M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.